EVOLVA HOLDING SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9 CHF | -2.17% |
|
-5.26% | +25.00% |
| 04-15 | Evolva Shareholders Pass Resolutions to Revoke Liquidation, Delisting | MT |
| 03-26 | Evolva Secures Temporary Exemption from Listing Rules Amid Liquidation | MT |
| Sales 2022 | 15.54M 16.98M 23.2M | Sales 2023 | 4.16M 4.54M 6.21M | Capitalization | 4.9M 5.36M 7.32M |
|---|---|---|---|---|---|
| Net income 2022 | -43M -46.99M -64.2M | Net income 2023 | -101M -110M -151M | EV / Sales 2022 | 6.5 x |
| Net Debt 2022 | 9.91M 10.84M 14.8M | Net cash position 2023 | 5.84M 6.38M 8.72M | EV / Sales 2023 | -0.23 x |
| P/E ratio 2022 |
-2.02
x | P/E ratio 2023 |
-0.05
x | Employees | 49 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evolva Holding SA
More recommendations
More press releases
More news
| 1 day | -2.17% | ||
| 1 week | -5.26% | ||
| Current month | -10.89% | ||
| 1 month | -4.66% | ||
| 3 months | +40.62% | ||
| 6 months | +8.17% | ||
| Current year | +25.00% |
1 week
0.90
0.95
1 month
0.901.01
Current year
0.621.09
1 year
0.6214.40
3 years
0.6246.95
5 years
0.6293.50
10 years
0.62465.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 22-02-07 | |
Gerhard Lobmaier
COO | Chief Operating Officer | 55 | 20-12-31 |
Astrid Schäfer
CTO | Chief Tech/Sci/R&D Officer | 51 | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 60 | 20-04-14 | |
Beat In-Albon
BRD | Director/Board Member | 72 | 20-04-14 |
Andreas Pfluger
BRD | Director/Board Member | 64 | 22-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 0.9 | -2.17% | 3,176 |
| 24-05-23 | 0.92 | -3.16% | 12,597 |
| 24-05-22 | 0.95 | +5.56% | 9,404 |
| 24-05-21 | 0.9 | -5.26% | 1,654 |
| 24-05-17 | 0.95 | +5.56% | 924 |
Delayed Quote Swiss Exchange, May 24, 2024 at 11:30 am
More quotes
Evolva Holding Ltd is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +25.00% | 7.1M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- EVE Stock
